Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10352 plus Fulvestrant in Advanced Breast Cancer
NCT05504213Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jan 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-10352 in breast cancer (3 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose, Maximum Applicable Dose and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
HS-10352
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05504213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504213.